Compassionate Use of Psilocybin – Current and Future Developments

In the last decade studies on psychedelic substances have demonstrated beneficial and sustainable effects on depression, Generalized Anxiety Disorder, PTSD and substance use disorders. Some substances like psilocybin are in Phase III study, i.e. close to approval in the health systems.
In addition to this, the German government has now approved the treatment of depression with psilocybin outside of studies – in the framework of a so-called Compassionate Use program.

The evening is about explaining why and how this happened and what the future of these substances in mental health and human development could look like.

Program

15:00 – 15:45
🔴 What is Compassionate Use and how do we use psilocybin at the OVID Clinic Berlin?
Dr. med. Andrea Jungaberle

15:45 – 16:30
🔴 What is the role of community in psychedelic integration?
Dr. Marvin Däumichen & Inna Krylovetska

Break – 20 min

16:50 – 17:20
🔴 Preparing, Experiencing, and Integrating in Psilocybin-Assisted Therapy: Patient Perspectives
Christopher Schmidt, M.Sc.

17:25 – 17:55
🔴 What’s the next step in bringing psychedelics into public healthcare?
Dr. sc. hum. Henrik Jungaberle

Break - 20 min

18:15 – 19:00
🔴 Panel discussion: What do we need to practice Psychedelic Therapy: Resources and Challenges
Dr. med. Andrea Jungaberle, Ines Mahr MSc, Dipl.-Psych. Inna Krylovetska
 

19:10 – 19:50
🔴 Experiential Experiments
– Digital medicine and the Virtual Reality Pod (VR)  - Dr. Prateep Beed
– Metaphoric Cards as Integration of Psychedelic Experience - Inna Krylovetska 
– Meditation Exercise - Dr. sc. hum. Henrik Jungaberle

19:50 – 20:30
Networking & reflections